EFFICIENT AND NON-GENETICALLY MODIFIED IPSC-INDUCED, INDUSTRIALIZED SINGLE CLONE SELECTION PLATFORM, AND USE

Abstract

Disclosed is an efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and a use. The platform can efficiently perform reprogramming, and only requires the use of a minimal number of reprogramming factors (OCT4, SOX2, E6, E7). During the single clone separation stage of the present invention, SSEA4/TRA-1-60 is used as a screening marker, and a large number of single cell clones are obtained by means of flow cytometry. The platform described in the present invention has advantages such as high reprogramming efficiency, high safety, easy operation, and large-scale production.

Claims

1. A reprogramming factor combination for reprogramming somatic cells into inducing pluripotent stem cells, characterized in that the reprogramming factor combination is selected from OCT4, SOX2, E6, E7, KLF4, L-MYC, LIN28, NANOG, SV40LT; preferably, the reprogramming factor combination is OCT4, SOX2, E6, E7; more preferably, a form of the reprogramming factor combination includes DNA, RNA, and protein; most preferably, the DNA is cDNA and the RNA is mRNA.

2. The reprogramming factor combination according to claim 1, characterized in that the reprogramming factor combination further comprises a reprogramming factor carrier for reprogramming somatic cells into inducing pluripotent stem cells, the reprogramming factor carrier comprises a reprogramming factor carrier obtained by encoding the reprogramming factor according to claim 1 in one and/or more skeleton carriers; preferably, the skeleton carrier includes pEGFP N1, pCMVp-NEO-BAN, PEGFP, PEGFT actin, pSV2, and CMV4; more preferably, the skeleton carrier is pEGFP N1; preferably, the reprogramming factor carrier includes one and/or more of the following reprogramming factor carriers: carriers encoding OCT4, carriers encoding SOX2, carriers encoding E6, carriers encoding E7, carriers encoding OCT4 and SOX2, carriers encoding OCT4 and E6, carriers encoding OCT4 and E7, carriers encoding SOX2 and E6, carriers encoding SOX2 and E7, carriers encoding E6 and E7, carriers encoding OCT4 and SOX2 and E6 Carriers encoding OCT4 and SOX2 and E7, carriers encoding OCT4 and E6 and E7, carriers encoding SOX2 and E6 and E7, carriers encoding OCT4 and SOX2 and E6 and E7; more preferably, the reprogramming factor carrier includes two types of reprogramming factor carriers: carriers encoding OCT4 and SOX2, and carriers encoding E6 and E7; most preferably, OCT4 and SOX2 in the carrier encoding OCT4 and SOX2 are connected through a spacer sequence and/or directly connected; most preferably, OCT4 and SOX2 in the carrier encoding OCT4 and SOX2 are connected through a spacer sequence; most preferably, the spacer sequence includes IRES and/or self-cleaving peptide 2A; most preferably, the self-cleaving peptide 2A is selected from T2A, P2A, E2A, F2A; most preferably, the spacer sequence is IRES; most preferably, a connection mode of OCT4 and SOX2 in the carrier encoding OCT4 and SOX2 includes: OCT4, IRES, SOX2 sequentially connected in series, SOX2, IRES, OCT4 sequentially connected in series; most preferably, a connection mode of OCT4 and SOX2 in the carrier encoding OCT4 and SOX2 is that OCT4, IRES, and SOX2 are sequentially connected in series; most preferably, E6 and E7 in the carriers encoding E6 and E7 are connected and/or directly connected through interval sequences; most preferably, E6 and E7 in the carriers encoding E6 and E7 are connected through spacer sequences; most preferably, the spacer sequence includes IRES, self-cleaving peptide 2A, and/or any two nucleotides; most preferably, the self-cleaving peptide 2A is selected from T2A, P2A, E2A, F2A; most preferably, any two nucleotides are selected from AA, TT, CC, GG, AT, TA, AC, CA, AG, GA, TC, CT, TG, GT, CG, GC; most preferably, the spacer sequence is IRES; most preferably, the connection mode of E6 and E7 in the carrier encoding E6 and E7 includes: E6, IRES, E7 sequentially connected in series, E7, IRES, E6 sequentially connected in series; most preferably, the connection mode of E6 and E7 in the carrier encoding E6 and E7 is sequential series connection of E6, IRES, and E7; most preferably, the nucleotide sequences of the carriers encoding OCT4 and SOX2 are shown in SEQ ID NO: 1; most preferably, the nucleotide sequences of the carriers encoding E6 and E7 are shown in SEQ ID NO: 2.

3. A preparation method for inducing pluripotent stem cells derived from somatic cells, characterized in that the method comprises the following steps: delivering the reprogramming factor combination according to claim 1 to somatic cells; preferably, the delivery of the reprogramming factor combination is achieved by introducing the reprogramming factor carrier into somatic cells; more preferably, the methods of introducing include electro transfection, microinjection, gene gun, DEAE glucan, calcium phosphate co precipitation transfection, and artificial liposome methods; most preferably, the method of introducing is an electro transfection method; most preferably, the reprogramming factor carrier is the reprogramming factor carrier according to claim 2; most preferably, a dosage of the reprogramming factor carrier is: in 80 to 200,000 somatic cells/100 ?L, addition of 0.5-8 to ?g carriers encoding OCT4 and SOX2 and carriers encoding E6 and E7; preferably, somatic cells obtained by introducing reprogramming factor carriers are cultured; more preferably, somatic cells obtained by introducing reprogramming factor carriers are cultured in a cell culture plate; most preferably, the cell culture plate is a culture plate coated with extracellular matrix proteins; most preferably, the extracellular matrix protein includes laminin; most preferably, the laminin is human laminin 521; most preferably, the cell culture plate also includes hematopoietic stem cells; more preferably, on the third day of cultivation, half of the medium is changed, and the E8 medium is used to continue cultivation for 2-4 days until full medium change, the E8 medium is used to continue cultivation until a large number of clones are formed; most preferably, the obtained clones are screened, labeled, and sorted to obtain somatic derived induced pluripotent stem cells; most preferably, screening markers include SSEA4, TRA-1-60, SSEA1, TRA-1-81, SSEA3, OCT4, SOX2, and NANOG; most preferably, the screening markers are selected from SSEA4, TRA-1-60, SSEA1, TRA-1-81; most preferably, the screening markers are SSEA4, TRA-1-60; most preferably, the sorting is carried out using flow cytometry sorting technology; preferably, the somatic cells include peripheral mononuclear blood cells, fibroblasts, umbilical cord blood cells, fibroblast like synovial cells, myocardial cells, liver cells, neural cells, hematopoietic stem cells, pancreatic islet cells, gastric epithelial cells, B lymphocytes, T lymphocytes, adipocytes, pancreas ? Cells, keratinocytes, mesenchymal stromal cells, epithelial cells, and endothelial cells.

4. An application, characterized in that the application comprises any of the following: (1) as a somatic derived induced pluripotent stem cell or cell population; (2) as a reprogrammed somatic cell; (3) as a culture medium for reprogramming somatic cells into inducing pluripotent stem cells; (4) as a kit for generating induced pluripotent stem cells; (5) as a pharmaceutical composition.

5. The application according to claim 4, characterized in that the reprogrammed somatic cell is a cell obtained by introducing the reprogramming factor carrier for reprogramming somatic cells into inducing pluripotent stem cells into a somatic cell; preferably, the methods of introducing include electro transfection, microinjection, gene gun, DEAE glucan, calcium phosphate co precipitation transfection, and artificial liposome methods; more preferably, the method of introducing is an electro transfection method; preferably, the somatic cells include peripheral mononuclear blood cells, fibroblasts, umbilical cord blood cells, fibroblast like synovial cells, myocardial cells, liver cells, neural cells, hematopoietic stem cells, pancreatic islet cells, gastric epithelial cells, B lymphocytes, T lymphocytes, adipocytes, and pancreas ? Cells, keratinocytes, mesenchymal stromal cells, epithelial cells, endothelial cells.

6. The application according to claim 4, characterized in that the culture medium for reprogramming somatic cells into inducing pluripotent stem cells is supplemented with a culture medium selected from OCT4 protein, SOX2 protein, E6 protein, E7 protein, KLF4 protein, L-MYC protein, LIN28 protein, NANOG protein, SV40LT protein; preferably, the culture medium is supplemented with OCT4 protein, SOX2 protein, E6 protein, and E7 protein.

7. The application according to claim 4, characterized in that the kit for generating induced pluripotent stem cells comprises a reprogramming factor combination for reprogramming somatic cells into inducing pluripotent stem cells, a reprogramming factor carrier for reprogramming somatic cells into inducing pluripotent stem cells, and/or reprogrammed somatic cells.

8. The application according to claim 4, characterized in that the pharmaceutical composition comprises the somatic derived induced pluripotent stem cells or cell populations; preferably, the pharmaceutical composition also includes pharmaceutically acceptable carriers.

9. (canceled)

10. The application according to claim 4, characterized in that the application includes: (1) the application of E6 and E7 in the preparation of induced pluripotent stem cells derived from somatic cells; (2) the application of the reprogramming factor combination for reprogramming somatic cells into inducing pluripotent stem cells in the preparation of induced pluripotent stem cells derived from somatic cells; (3) the application of the reprogramming factor carrier for reprogramming somatic cells into inducing pluripotent stem cells in the preparation of induced pluripotent stem cells derived from somatic cells; (4) the application of somatic derived induced pluripotent stem cells or cell populations, and reprogrammed somatic cells in producing precursor cells for differentiation and/or differentiation; (5) the application of somatic derived induced pluripotent stem cells or cell populations and reprogrammed somatic cells in constructing a disease model; (6) the application of somatic derived induced pluripotent stem cells or cell populations and reprogrammed somatic cells in constructing a tumor stem cell model; (7) the application of somatic derived induced pluripotent stem cells or cell populations and reprogrammed somatic cells in the preparation of drugs for treating diseases; (8) the application of somatic derived induced pluripotent stem cells or cell populations and reprogrammed somatic cells in screening candidate drugs for treating diseases; (9) the application of somatic derived induced pluripotent stem cells or cell populations and reprogrammed somatic cells in drug evaluation for disease treatment; (10) the application of somatic derived induced pluripotent stem cells or cell populations and reprogrammed somatic cells in cell therapy of diseases; (11) the application of the somatic derived induced pluripotent stem cells or cell populations, and the reprogrammed somatic cells in cell transplantation and tissue repair; (12) the application of the somatic derived induced pluripotent stem cells or cell populations, and the reprogrammed somatic cells in organ regeneration; (13) the application of somatic derived induced pluripotent stem cells or cell populations and reprogrammed somatic cells in the preparation of targeted in vivo tumor lesion formulations; (14) the application of somatic derived induced pluripotent stem cells or cell populations and reprogrammed somatic cells in immune cell anti-tumor therapy; (15) the application of the culture medium for reprogramming somatic cells into inducing pluripotent stem cells in the preparation of induced pluripotent stem cells derived from somatic cells; (16) the application of the kit for generating induced pluripotent stem cells in the production of induced pluripotent stem cells; (17) the application of the pharmaceutical composition in the prevention and/or treatment of diseases; preferably, the diseases include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Down's syndrome, X chromosome vulnerability syndrome, Reiter syndrome, Huntington's disease, familial autonomic nervous dysfunction disease, schizophrenia, ataxia, diabetes, cardiovascular disease, age-related macular degeneration, myopic macular degeneration, Steger's disease, kidney disease Liver disease, lung disease, hemophilia, myeloma; preferably, the tumor includes melanoma, prostate cancer, breast cancer, lung cancer, kidney cancer, liver cancer, cervical cancer, vulva cancer, B-cell lymphoma, T-cell lymphoma, myeloma, leukemia, hematopoietic system tumor, thymoma, lymphoma, sarcoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, skin cancer, uterine cancer, endometrial cancer, adenocarcinoma, pancreatic cancer, colorectal cancer, anal cancer, bladder cancer, ovarian cancer Squamous cell carcinoma, basal cell carcinoma, brain cancer, angiosarcoma, vascular endothelial tumor, head and neck cancer, thyroid cancer, soft tissue sarcoma, osteosarcoma, testicular cancer, gastrointestinal cancer.

11. The application according to claim 4, characterized in that the somatic derived induced pluripotent stem cell or cell population is prepared using the preparation method for inducing pluripotent stem cells derived from somatic cells.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0127] The following is a detailed description of the embodiments of the present invention in conjunction with the accompanying drawings, wherein:

[0128] FIG. 1 is the flowchart of an efficient and non-genetically modified iPSC induction and industrial monoclonal selection platform developed by the present invention, as well as the flowchart of the current iPSC induction method, in which a of FIG. 1 shows the flowchart of the current iPSC induction method, and b of FIG. 1 shows the flowchart of the efficient and non-genetically modified iPSC induction and industrial monoclonal selection platform developed by the present invention;

[0129] FIG. 2 shows the morphology of iPSC reprogramming using OCT4-IRES-SOX2 and E6-E7 plasmids after PBMC electro transfection on the first day;

[0130] FIG. 3 shows the morphology of epithelial cells produced on the 7th day after iPSC reprogramming using OCT4-IRES-SOX2 and E6-E7 plasmids;

[0131] FIG. 4 shows the morphology of epithelial cells produced on day 20 after iPSC reprogramming using OCT4-IRES-SOX2 and E6-E7 plasmids;

[0132] FIG. 5 shows the results of OSE6-IPSC alkaline phosphatase staining using OCT4-IRES-SOX2 and E6-E7 plasmids;

[0133] FIG. 6 shows the OSE6-IPSC immunofluorescence results obtained using OCT4-IRES-SOX2 and E6-E7 plasmids;

[0134] FIG. 7 shows the flow cytometry results of OSE6-IPSC obtained using the OCT4-IRES-SOX2 and E6-E7 plasmids, in which a of FIG. 7 shows NANOG, b of FIG. 7 shows OCT4, c of FIG. 7 shows SOX2, d of FIG. 7 shows SSEA1, e of FIG. 7 shows SSEA4, f of FIG. 7 shows TRA-1-60, and g of FIG. 7 shows TRA-1-81;

[0135] FIG. 8 shows the HE staining results of OSE6-IPSC teratoma slices obtained using OCT4-IRES-SOX2 and E6-E7 plasmids, where a represents the hair follicle structure, b represents the cartilage structure, and c represents the digestive tract epithelial structure;

[0136] FIG. 9 shows the results of OSE6-IPSC karyotype detection using OCT4-IRES-SOX2 and E6-E7 plasmids.

DETAILED DESCRIPTION

[0137] The following will further elaborate on the present invention in conjunction with specific embodiments, which is only intended to explain the present invention and cannot be understood as a limitation of the present invention. Ordinary skilled person in this field can understand that various changes, modifications, substitutions, and variations can be made to these embodiments without departing from the principles and purposes of the present invention. The scope of the present invention is limited by the claims and their equivalents. The experimental methods in the following embodiments that do not specify specific conditions are usually tested under conventional conditions or according to the conditions recommended by the manufacturer.

Example 1: Construction of Reprogrammed Plasmid

1. Experimental Materials

[0138] The pEGFP N1 plasmid described in this embodiment was purchased from Addgene Company.

2. Experimental Methods

[0139] (1) Using the pEGFP N1 plasmid as the skeleton carrier and EcoR1 and Not1 as the cleavage sites; [0140] (2) Gene synthesis of OCT4-IRES-SOX2 and E6-E7 was carried out by Anhui General Biotechnology Co., Ltd., OCT4-IRES-SOX2 and E6-E7 were inserted between EcoR1 and Not1 of the pEGFP N1 plasmid, and the carriers were named OCT4-IRES-SOX2 and E6-E7; [0141] (3) the sequence of OCT4-IRES-SOX2 is shown in SEQ ID NO:1. OCT4 and SOX2 are sequentially connected through spacer sequences, with the spacer sequence being IRES. The IRES sequence can be replaced with self-cleaving 2A peptide (self-cleaving 2A peptide, 2A), including E2A, P2A, T2A, F2A, etc. [0142] (4) the sequence of E6-E7 is shown in SEQ ID NO:2. E6 and E7 are sequentially connected by a spacer sequence called IRES. The IRES sequence can be replaced by a self-cleaving 2A peptide (self-cleaving 2A peptide, 2A), including E2A, P2A, T2A, F2A, etc. The IRES sequence can also be replaced by any two nucleotides, such as AA, TT, CC, GG, AT, TA, AC, CA, AG, GA, TC, CT, TG, GT, CG, GC.

Example 2 PBMC Amplification Preparation Operation

1. Experimental Materials

[0143] Peripheral blood mononuclear cells (PBMCs) were purchased from STEMCELL Technologies under item #70072.2; StemSpan? SFEM II is purchased from STEMCELL Technologies under item #09655; StemSpan? The CD34+Expansion Supplement was purchased from STEMCELL Technologies under item #02691.

2. Experimental Methods

[0144] (1) Took out a 12 to 15 million PBMC that has been frozen from the liquid nitrogen tank, placed it in a hot water bath with a temperature of 37 to 40? C., gently shaked it, and when there were only small crystals left in the frozen tube, thoroughly disinfect the surface of the frozen tube with 75% alcohol, wiped off 75% alcohol with sterile gauze, and placed it on an ultra clean workbench; [0145] (2) added the cell suspension to a basic culture medium containing 10 mL of preheated hematopoietic stem cells using a pipette, gently mixed well, and then took samples for counting. At the same time, balance and centrifuge with 200 g for 10 minutes;

[0146] Among them, the hematopoietic stem cell basic culture medium group was composed by StemSpan? SFEM II and StemSpan? CD34+Expansion Supplement, configured according to the manufacturer's requirements; [0147] (3) After centrifugation, gently aspirate the supernatant with a pipette and resuspend the cells with 2 mL of hematopoietic stem cell expansion medium (preheated to 37? C.). Mix well and inoculated 1 mL of cell suspension per well onto a 12 well plate. Inoculated a total of 2 wells and culture them in a 37? C., 5% CO2 cell incubator; [0148] (4) After 3 to 6 days of cultivation until cell proliferation, large colonies can be formed, with a large number of colonies, most commonly found in areas with high cell density, and then subjected to electro transfection.

Example 3 PBMC Electro Transfection Operation

1. Experimental Materials

[0149] The reprogramming plasmids OCT4-IRES-SOX2 and E6-E7 constructed in Example 1 of the present invention, and the PBMC obtained from cultivation and amplification in Example 2 of the present invention.

2. Experimental Methods

[0150] (1) Gently blow the cells to be electro transfected (PBMC) and collected the cell suspension into a new 50 mL centrifuge tube; [0151] (2) washed the cell pores once with 2 mL DPBS, transferred the cleaning solution to the aforementioned 50 mL centrifuge tube, gently mixed well, and then took a sample for counting; [0152] (3) after balancing, centrifuged at 200 g for 10 minutes, centrifuged and count; [0153] (4) according to the counting results, the number of inoculated cells on the 6-well plate was 80 to 2 million cells per well; [0154] (5) after centrifugation, the cells were resuspended according to the cell count, resulting in a cell concentration of 0.8?10.sup.6-2.0?10.sup.6 cells/100 ?L. After resuspension, take 300 ?L cell suspension, i.e. 6 million cells, undergoes three electro transfection reactions; [0155] (6) According to each electro transfection reaction (80 to 2 million cells/100 ?L), added 0.5-8 ?g plasmids (OCT4-IRES-SOX2 and E6-E7).

Example 4 PBMC Reprogramming Operation

1. Experimental Materials

[0156] The PBMC obtained after electric transfection in Example 2 of the present invention; recombinant human laminin-521 was purchased from Thermo Fisher Scientific Co., Ltd., product number A29249; the E8 culture medium was purchased from Thermo Fisher Scientific Co., Ltd. with product number A1517001; TRYPLE was purchased from Thermo Fisher Scientific Co., Ltd. with product number 12604013; Alexa Fluor? 488 anti-human SSEA-4 Antibody is purchased from BioLegend Company with product number 330412; Alexa Fluor? The 594 anti-human TRA-1-60-R Antibody was purchased from Biogene Corporation under product number 330616.

2. Experimental Methods

[0157] (1) Transferred the electro transfected PBMC to a 6 cm well plate/culture dish coated with recombinant human laminin-521, added 2 mL of hematopoietic stem cells for expansion and culture, and placed them in a 37? C., 5% CO2 cell incubator for cultivation; [0158] (2) On the first day of observation and photography: at this point, some adherent cells can be seen; [0159] (3) On the third day and a half, changed the medium and continued cultivation using E8 medium; [0160] (4) On days 5-7, observed the number and morphological changes of adherent cells: the cell morphology will gradually change from a polar neuroid like cell to a short rod-shaped one, and then to an epithelioid one. The nuclear region and nucleoli will gradually become apparent, and deformed cells can be observed to form small cell colonies; performed a complete fluid exchange on the cells, used E8 medium, and continued cultivation; [0161] (5) On the 7th to 21st days, the cells were completely changed daily using E8 culture medium; generated a large number of clones when the clone size is 100 ?m-1 mm and when the number of cells is approximately 100-10000, used 0-20 ?M ROCK signaling pathway inhibitor Thiazovivin to treat cells for 2 hours, and the clones were digested into single cells using TRYPLE; [0162] (6) Collected cells into a 12 mL centrifuge tube, centrifuged, removed supernatant, and cleaned cells twice with DPBS; [0163] (7) Follow the supplier's instructions, used Alexa Fluid? 488 anti-human SSEA-4 Antibody and Alexa Fluor? 594 anti-human TRA-1-60-R Antibody to label cells; [0164] (8) The labeled cells were sorted on the flow cytometry platform. SSEA-4 and TRA-1-60 single or double positive cells were seeded on a 96 cm well plate coated with human laminin-521, and cultured in a 5% CO2 cell incubator at 37? C.; [0165] (9) Continued to culture in a 96 well plate for 7-14 days, and performed a full fluid exchange operation every day. When the cell convergence rate is about 70%-80%, the cells are subcultured into a 48 well plate; [0166] (10) Continued to cultivate cells, and when the cell convergence rate is about 70%-80%, proceed with passage operations. The passage vessel requirements are: P0 (24 well plate).fwdarw.P1 (12 well plate).fwdarw.P2 (T25 bottle).fwdarw.P3 (T25 bottle).fwdarw.P4 (T25/T75 bottle), etc.

3. Experimental Results

[0167] The flowchart of the efficient and genetically modified iPSC induction and industrial monoclonal selection platform developed by the present invention is shown in b of FIG. 1, and the current iPSC induction method flowchart is shown in a of FIG. 1;

[0168] The experimental results showed that iPSC reprogramming using OCT4-IRES-SOX2 and E6-E7 plasmids resulted in normal cell morphology, fewer cell colonies, clean background, and fewer dead cells after PBMC electroporation on the first day (see FIG. 2); IPSC reprogramming was performed using OCT4-IRES-SOX2 and E6-E7 plasmids, and on the 7th day, epithelioid cells were produced without fully exhibiting clonal growth (see FIG. 3); Using OCT4-IRES-SOX2 and E6-E7 plasmids for iPSC reprogramming, on the 20th day, epithelioid cells were produced and showed clonal growth (see FIG. 4).

Example 5 iPSC Dry Identification

1. Experimental Methods

[0169] (1) Take approximately 3?10.sup.4 iPS cells for test sample, 1?10.sup.4 cells per hole were seeded onto a 24 well cell culture plate coated with Matrigel, totally 3 wells. 1 mL of freshly prepared E8 complete culture medium containing ROCK was added to each well and incubated at 37? C. in a 5% CO2 cell culture incubator for 24 hours; [0170] (2) On the second day, performed a fluid change operation, discarded the old culture medium, added 1 mL of E8 complete culture medium to each well, and cultured in a 37? C., 5% CO2 cell incubator until the convergence reaches about 50%, and prepared for staining when no colonies are formed; [0171] (3) Prepared alkaline phosphatase staining solution (AP staining solution), and the composition and content of the alkaline phosphatase staining solution are shown in Table 1; [0172] (4) Absorbed and discarded the cell culture medium to be tested in a 24 well plate, and cleaned it twice with DPBS for 1 minute each time; [0173] (5) Then added 200 ?L 4% paraformaldehyde to each hole and blocked it in a dark place for 20 minutes; [0174] (6) Absorbed and discarded the blocked solution, then cleaned twice with DPBS, each time for 1 minute; [0175] (7) Then added 200 ?L AP staining solution to each hole, dark staining for 1 hour; [0176] (8) After staining, rinsed 1-2 times with sterile water to remove floating colors. Added sterile water to the hole, observed under an inverted microscope, and take photos for archiving.

TABLE-US-00001 TABLE 1 Composition and Content of Alkaline Phosphatase Staining Solution (AP Staining Solution) Alkaline phosphatase Alkaline phosphatase 3 mL 3.03 mL staining solution chromogenic buffer (AP staining solution) BCIP solution (300X) 10 ?L NBT solution (150X) 20 ?L

2. Experimental Results

[0177] The experimental results showed that iPSCs were positively expressed by alkaline phosphatase staining (see FIG. 5), indicating high alkaline phosphatase activity in iPSCs and iPSCs is in their undifferentiated state.

Example 6 Immunofluorescence Identification

1. Experimental Materials

[0178] The information of the primary and secondary antibodies used in this example is as follows: Anti Nanog antibody (Abcam company, product number: ab109250); Mouse anti SSEA-4 (Abcam Company, product number ab16287); Mouse anti TRA-1-60 (Abcam company, product number: ab16288); Anti Oct4 antibody (Abcam company, product number: ab19857); Recombinant Anti SOX2 antibody [EPR3131] (Abcam Company, ab92494); Goat anti Mouse IgG3 Cross Adsorbed Secondary Antibody, Alexa Fluor 488 (Invitrogen, A-21151); Goat anti Mouse IgM (Heavy chain) Cross Adsorbed Secondary Antibody, Alexa Fluor 488 (Invitrogen, A-21042); Donkey anti rabbit IgG (H+L) Highly Cross Adsorbed Secondary Antibody, Alexa Fluor 594 (Invitrogen, A-21207); Donkey anti rabbit IgG (H+L) Highly Cross Adsorbed Secondary Antibody, Alexa Fluor 488 (Invitrogen, A-21206).

2. Experimental Methods

[0179] (1) Soaked the slides of cells that have already crawled on a 24 well culture plate with PBS three times, each time for 3 minutes; [0180] (2) blocked the slide at room temperature with 4% paraformaldehyde for 15 minutes, and soaked the slide with PBS three times for 3 minutes each time; [0181] (3) 0.5% Triton X-100 (prepared with 5% BSA) is permeability at room temperature for 20 minutes (this step is omitted for antigens expressed on the cell membrane); [0182] (4) blocked at room temperature with 5% BSA for 1 hour; [0183] (5) removed the blocking liquid and added 400 ?L primary antibody to each hole, incubated overnight at 4? C.; [0184] the above steps (1)-(5) are for the first day of work; [0185] (6) added fluorescent secondary antibody: soaked PBST 3 times for 5 minutes each time, add diluted fluorescent secondary antibody, incubated at room temperature for 1 hour, and soaked PBST 3 times for 5 minutes each time; started from adding fluorescent secondary antibodies, all subsequent steps should be carried out in a darker area as much as possible; [0186] (7) re stained nucleus: added DAPI dropwise, incubated in dark for 5 minutes, stained the specimen with nucleus, PBST for 5 minutes?4 times to wash off excess DAPI; [0187] (8) added 500 ?L PBS, shoot on camera.

3. Experimental Results

[0188] The results showed that after immunofluorescence staining, OSE6-IPSC obtained using OCT4-IRES-SOX2 and E6-E7 plasmids expressed stem cell surface markers SOX2, OCT4, NANOG, SSEA4, TRA-1-60 (see FIG. 6), indicating the stemness of the iPSC.

Example 7 Flow Detection

1. Experimental Materials

[0189] The antibodies used in this example are all purchased from Biogene Company, and the antibodies include: Alexa Fluor? 594 anti Nano Anti body (674204); Alexa Fluor? 594 anti Oct4 (Oct3) Anti body (653708); Alexa Fluor? 488 anti human SSEA-4 Anti body (330412); PE anti mouse/human CD15 (SSEA-1) Anti body (125605); Alexa Fluor? 488 anti human TRA-1-60-R Antibody (330613); Alexa Fluor? 488 anti human TRA-1-81 Anti body (330709); Alexa Fluor? 555 Mouse anti Sox2 (560293).

2. Experimental Methods

[0190] (1) Centrifuged iPSC cells in a 15 mL centrifuge tube with 200 g for 10 minutes, discarded the supernatant, transfer to 1.5 mL EP tubes, added 1 mL of fixative solution (4% paraformaldehyde), and incubated at room temperature for 10 minutes; [0191] (2) After rapid centrifugation with a micro centrifuge, removed 1.5 mL of EP tube fixative solution and washed 3 times with 0.5 mL of DPBS; [0192] (3) After rapid centrifugation, removed 1.5 mL of DPBS from the EP tube, added 1 mL of 5% BSA blocking solution, and let stand at room temperature for 30 minutes; [0193] (4) Group, package, and label the blocked samples according to the set experiment; [0194] (5) The supernatant of the experimental group was aspirated and discarded, and 0.2 mL of primary antibody working solution was added to the experimental well. The negative control group was left untreated and incubated at room temperature for 1 hour; [0195] (6) Absorbed and discard the supernatant, added 0.2 mL of DPBS to each well and washed three times; [0196] (7) Added 0.2 mL of secondary antibody working solution to each well and incubated at room temperature in dark for 1 hour; [0197] (8) Removed the supernatant and added 0.5 mL of DPBS to each well for washing three times; [0198] (9) Prepared the flow sample for flow cytometry, and saved the document after analysis is completed.

3. Experimental Results

[0199] The results of OSE6-IPSC flow cytometry using OCT4-IRES-SOX2 and E6-E7 plasmids showed that NANOG, OCT4, SOX2, SSEA4, TRA-1-60, and TRA-1-81 were all positive, while SSEA1 was negative (see a-g of FIG. 7), consistent with the gene expression characteristics of iPSC stem cells, further indicating that the iPSC has stemness.

Example 8 Identification of Teratoma Formation

1. Experimental Methods

[0200] (1) Prepared iPSC cells 6?10.sup.6 cells per mouse were subcutaneously injected into the right armpit of the mouse's forelimb, with an injection volume of 0.2 mL/point per mouse. After injection, the mice were observed for 8 weeks, including tumor formation at the transplantation site and the general condition of the mice; [0201] (2) After the animal was euthanized, if there is a tumor, the tumor should be removed, the material should be taken, the tumor should be weighed, and the tumor should be subjected to histopathological examination.

2. Experimental Results

[0202] The HE staining results of OSE6-IPSC teratoma sections obtained using OCT4-IRES-SOX2 and E6-E7 plasmids are shown in a-c of FIG. 8. Among them, a is the hair follicle structure, b is the cartilage structure, and c is the digestive tract epithelial structure, indicating that the obtained iPSC can successfully form teratomas and has pluripotency for in vivo differentiation.

Example 9 Karyotype Detection

1. Experimental Methods

[0203] (1) Approximately 3?10.sup.5 iPS cells for the test sample were seeded into T25 cell culture flasks coated with Matrigel, and 1 mL of freshly prepared E8 complete culture medium containing ROCK was added to each well. They were incubated at 37? C. in a 5% CO2 cell culture incubator for 24 hours; [0204] (2) The next day, used E8 complete culture medium to replace the solution and sent it for external testing. The external testing unit was Jinan Aidikang Medical Testing Center.

2. Experimental Results

[0205] The karyotype detection results of OSE6-IPSC obtained using the OCT4-IRES-SOX2 and E6-E7 plasmids in this example are shown in FIG. 9. 46 chromosomes with normal numbers and XX sex chromosomes are visible, indicating a female karyotype and no abnormalities in chromosome structure. This indicates that the OSE6-IPSC obtained using the OCT4-IRES-SOX2 and E6-E7 plasmids does not exhibit chromosomal aberrations and all exhibit normal karyotypes.

Comparison of iPSC Reprogramming Efficiency in Example 10

1. Experimental Materials

[0206] The commercial reprogramming kit CD34+Progenitor Reprogramming Kit used in this example was purchased from STEMCELL Technologies under item #05925.

2. Experimental Methods

[0207] (1) Prepared PBMC cells according to the PBMC amplification method; [0208] (2) Used OCT4-IRES-SOX2 plasmid (OS) alone, E6-E7 plasmid (E6/E7) alone, and OCT4-IRES-SOX2 and E6-E7 plasmids (OSE6) according to PBMC reprogramming method; [0209] (3) Used the commercial reprogramming kit CD34+Progenitor Reprogramming Kit to reprogram according to the instructions; [0210] (4) Compared the reprogramming efficiency of the four schemes mentioned above and the resulting number of clones.

2. Experimental Results

[0211] The results showed that the reprogramming efficiency using OCT4-IRES-SOX2 alone (OS), E6-E7 alone (E6/E7), OCT4-IRES-SOX2 and E6-E7 alone (OSE6), and commercial reprogramming kits (kit) were 0, 0, 2%-5%, and 0.2%-4.9%, respectively (see Table 2); The number of clones obtained using OCT4-IRES-SOX2 reprogramming (OS) alone, E6-E7 reprogramming (E6/E7) alone, OCT4-IRES-SOX2 and E6-E7 reprogramming (OSE6), and commercial reprogramming kits (kits) were 0, 0, 125?30, and 11?5, respectively (see Table 3), indicating that the reprogramming efficiency using OCT4-IRES-SOX2 and E6-E7 reprogramming (OSE6) is not only better than the currently available commercial reprogramming kits (kits), the final number of monoclonal clones obtained is also much higher than that of commercial reprogramming kits, which can be used for industrial production.

TABLE-US-00002 TABLE 2 Reprogramming Efficiency Results Using OS, E6/E7, OSE6, Kit Reprogramming Reprogramming factor combinations OS E6/E7 OSE6 kit Reprogramming 0 0 2%-5% 0.2%-4.9% Efficiency

TABLE-US-00003 TABLE 3 The final number of clones obtained by reprogramming using OS, E6/E7, OSE6, and kit Reprogramming factor combinations OS E6/E7 OSE6 kit Reprogramming 0 0 125 ? 30 11 ? 5 factor combinations/ 10000 cells

[0212] The explanation of the above embodiments is only for understanding the methods and core ideas of the present invention. It should be pointed out that for ordinary technical personnel in this field, without departing from the principles of the present invention, several improvements and modifications can be made to the present invention, which will also fall within the scope of protection of the claims of the present invention.